Zelluna
Updated: March 28, 2026
CEO - Namir Hassan
Country: Norway | Funding: $13.1M (+)
Founded: 2016
Website: https://www.zelluna.com/
Zelluna Immunotherapy is developing a unique and proprietary TCR-NK cell therapy platform for the treatment of cancer. The therapy utilizes human (donor) natural killer (NK) cells, driven by T-cell receptors (TCRs), which are administered to patients. TCRs provide precise targeting of cancer cells and enable NK cells to find and destroy cancer cells within the patient's body. Zelluna's development pipeline targets a combination of clinically or preclinically validated antigens expressed in a broad range of solid tumors, providing high potential for patient impact and a significant market opportunity. The company's undergoing clinical trials include the following indications: NSCLC, ovarian cancer, sarcoma, breast cancer, gastric cancer, lung cancer, pancreatic cancer, cervical cancer.
Founded: 2016
Website: https://www.zelluna.com/
Zelluna Immunotherapy is developing a unique and proprietary TCR-NK cell therapy platform for the treatment of cancer. The therapy utilizes human (donor) natural killer (NK) cells, driven by T-cell receptors (TCRs), which are administered to patients. TCRs provide precise targeting of cancer cells and enable NK cells to find and destroy cancer cells within the patient's body. Zelluna's development pipeline targets a combination of clinically or preclinically validated antigens expressed in a broad range of solid tumors, providing high potential for patient impact and a significant market opportunity. The company's undergoing clinical trials include the following indications: NSCLC, ovarian cancer, sarcoma, breast cancer, gastric cancer, lung cancer, pancreatic cancer, cervical cancer.
